Anaptys Sees Positive Trial Results for Imsidolimad Psoriasis Treatment
By Chris Wack
Anaptys said Monday that it saw positive top-line results from its global Phase 3 trial evaluating the safety and efficacy of imsidolimab in patients with generalized pustular psoriasis flares.
The stock was halted at $19.25 in premarket trading.
The biotechnology company said that investigational imsidolimab met its primary endpoint in the study population achieving rapid clearance of pustulation, erythema and scaling after a single dose of 750mg IV imsidolimab.
Top-line data also demonstrate a favorable safety and tolerability profile.
All adverse effects reported in imsidolimab-treated patients were mild or moderate and balanced across imsidolimab-treated versus placebo patients. No serious or severe adverse effects were reported in imsidolimab-treated patients.
Anaptys plans to present comprehensive data from the trial in the second half of 2024. The company anticipates filing a biologics license application with the U.S. Food and Drug Administration by the third quarter of 2024.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
October 09, 2023 08:28 ET (12:28 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
This Cheap Stock Is Still a Buy Even After 50% Rally
-
10 Top-Performing Dividend Stocks of Q3 2024
-
33 Undervalued Stocks
-
Communication Services: Cable’s Broadband Dominance Isn’t as Strong as It Once Was
-
Technology: Strength Continues, With Software Presenting the Best Buying Opportunities
-
Best- and Worst-Performing Stocks of Q3 2024
-
Top Stocks to Own From the Best Fund Managers
-
2 Cheap Stocks Top Managers Have Been Buying